High-dose cytosine arabinoside (Ara-C) in colorectal cancer.

Por Kanojia, M., Kantarjian, H., Ajani, J., Barlogie, B.
Publicado em 1983

New drugs in acute myeloid leukemia

Por Kadia, T. M., Ravandi, F., Cortes, J., Kantarjian, H.
Publicado no Ann Oncol (2016)

Cefamandole bile levels in patients with hepatobiliary disease.

Por Uwaydah, M, Kantarjian, H, Osseiran, M, Bal'a, F
Publicado em 1982

Treatment of typhoid fever with cefamandole.

Por Uwaydah, M, Nassar, N T, Harakeh, H, Vartivarian, S, Talhouk, A, Kantarjian, H
Publicado em 1984

Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.

Por Talpaz, M, Estrov, Z, Kantarjian, H, Ku, S, Foteh, A, Kurzrock, R
Publicado em 1994

Disseminated Geotrichum candidum infection.

Por Kassamali, H, Anaissie, E, Ro, J, Rolston, K, Kantarjian, H, Fainstein, V, Bodey, G P
Publicado em 1987

Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients

Por Samanta, AK, Chakraborty, SN, Wang, Y, Kantarjian, H, Sun, X, Hood, J, Perrotti, D, Arlinghaus, RB
Publicado em 2009

Phase I Study of INNO-406, a Dual Abl/Lyn Kinase Inhibitor, in Philadelphia Chromosome-Positive Leukemias Post-Imatinib Resistance or Intolerance

Por Kantarjian, H., le Coutre, P., Cortes, J., Pinilla-Ibarz, J., Nagler, A., Hochhaus, A., Kimura, S., Ottmann, O.
Publicado em 2010

Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial

Por Platzbecker, U, Sekeres, M A, Kantarjian, H, Giagounidis, A, Mufti, G J, Jia, C, Yang, A S, Fenaux, P
Publicado no Leukemia (2014)

Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells.

Por Upadhyaya, G, Guba, S C, Sih, S A, Feinberg, A P, Talpaz, M, Kantarjian, H M, Deisseroth, A B, Emerson, S G
Publicado em 1991

A phosphatase activity present in peripheral blood myeloid cells of chronic myelogenous leukemia patients but not normal individuals alters nuclear protein binding to transcription...

Por Seong, D C, Sims, S, Johnson, E, Howard, O M, Reiter, B, Hester, J, Talpaz, M, Kantarjian, H, Deisseroth, A
Publicado em 1990

A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis

Por Quintás-Cardama, A, Tong, W, Kantarjian, H, Thomas, D, Ravandi, F, Kornblau, S, Manshouri, T, Cortes, JE, Garcia-Manero, G, Verstovsek, S
Publicado no Leukemia (2008)

Pretreatment of cytokinetics in acute myelogenous leukemia. Age-related prognostic implications.

Por Kantarjian, H M, Barlogie, B, Keating, M J, Hall, R R, Smith, T L, McCredie, K B, Freireich, E J
Publicado em 1985

AML with t(10;11): A pathological entity with distinct clinical presentation

Por DiNardo, CD, Tang, G, Pemmaraju, N, Wang, S, Pike, A, Garcia-Manero, G, Cortes, J, Bueso-Ramos, C, Kantarjian, H
Publicado no Clin Lymphoma Myeloma Leuk (2014)

Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses

Por Wetzler, M, Kantarjian, H M, Nicolini, F E, Lipton, J H, Akard, L, Baccarani, M, Khoury, H J, Li, E, Munteanu, M, Cortes, J
Publicado no Blood Cancer J (2015)

Phase II Randomized Study of p53 Antisense Oligonucleotide (Cenersen) plus Idarubicin With or Without Cytarabine in Refractory and Relapsed Acute Myeloid Leukemia

Por Cortes, J, Kantarjian, H, Ball, E D, DiPersio, J, Kolitz, J E, Fernandez, H F, Goodman, M, Borthakur, G, Baer, Maria R, Wetzler, Meir
Publicado no Cancer (2011)

Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies

Por Ravandi, F, Pigneux, A, DeAngelo, D J, Raffoux, E, Delaunay, J, Thomas, X, Kadia, T, Kantarjian, H, Scheuenpflug, J, Zhao, C, Guo, W, Smith, B D
Publicado no Blood Cancer J (2015)

Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors

Por Cortes, J., Digumarti, R., Parikh, P.M., Wetzler, M., Lipton, J.H., Hochhaus, A., Craig, A.R., Benichou, A.-C., Nicolini, F.E., Kantarjian, H.M.
Publicado no Am J Hematol (2013)

Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia

Por Gong, Z, Medeiros, L J, Cortes, J E, Zheng, L, Khoury, J D, Wang, W, Tang, G, Loghavi, S, Luthra, R, Yang, W, Kantarjian, H M, Hu, S
Publicado no Blood Cancer J (2017)

Lack of association of IDH1, IDH2, and DNMT3A mutations with outcome in older patients with AML treated with hypomethylating agents

Por DiNardo, CD, Patel, KP, Garcia-Manero, G, Luthra, R, Pierce, S, Borthakur, G, Jabbour, E, Kadia, T, Pemmaraju, N, Konopleva, M, Faderl, S, Cortes, J, Kantarjian, H, Ravandi, F
Publicado em 2014